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Background: Around 9–15% of ischemic strokes are related to internal carotid
artery (ICA)-stenosis ≥50%. However, the extent to which ICA-stenosis <50% causes
ischemic cerebrovascular events is uncertain. We examined the relation between plaque
cross-sectional area and length and the risk of ischemic stroke or TIA among patients
with ICA-stenosis of 20–40%.
Methods: We retrospectively identified patients admitted to the Department of
Neurology, University Hospital of Würzburg, from January 2011 until September
2016 with ischemic stroke or TIA and concomitant ICA-stenosis of 20–40%, either
symptomatic or asymptomatic. Plaque length and cross-sectional area were assessed
on ultrasound scans.
Results: We identified 41 patients with ischemic stroke or TIA and ICA-stenosis of
20–40%; 14 symptomatic and 27 asymptomatic. The plaque cross-sectional area was
significantly larger among symptomatic than asymptomatic ICA-stenosis; median values
(IQR) were 0.45 (0.21–0.69) cm2 and 0.27 (0.21–0.38) cm2, p = 0.03, respectively. A
plaque cross-sectional area ≥0.36 cm2 had a sensitivity of 71% and a specificity of
76% for symptomatic compared with asymptomatic ICA-stenosis. In a sex-adjusted
multivariate logistic regression, a plaque cross-sectional area ≥0.36 cm2 and a plaque
length ≥1.65 cm were associated with an OR (95% CI) of 5.54 (1.2–25.6), p = 0.028
and 1.78 (0.36–8.73), p = 0.48, respectively, for symptomatic ICA-stenosis.
Conclusion: Large plaques might increase the risk of ischemic stroke or TIA among
patients with low-grade ICA-stenosis of 20–40%. Sufficiently powered prospective
longitudinal cohort studies are needed to definitively test the stroke risk stratification
value of carotid plaque length and cross-sectional area in the setting of current optimal
medical treatment.
Keywords: ischemic stroke, carotid atherosclerosis, carotid stenosis, plaque cross-sectional area, length of
stenosis, carotid ultrasound
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INTRODUCTION
Internal carotid artery (ICA)-stenosis ≥50% causes around 9–
15% of ischemic strokes (1). Evidence is accumulating that low-
grade ICA-stenosis bears also a high-risk for ischemic stroke
(2–5); if no optimal medical treatment is implemented, the
annual ipsilateral stroke rate associated with mild-to-moderate
asymptomatic ICA-stenosis is 0.1–1.6% compared to 2–3.3%
among severe stenotic degrees (6, 7). Previous studies pointed
to carotid plaque area as a useful parameter to stratify the
risk of stroke and even to monitor preventive treatment of
cerebrovascular and major vascular diseases (8, 9). In the current
work, we investigated whether the carotid plaque cross-sectional
area and/or length aremore prominent among symptomatic than
asymptomatic ICA-stenosis of 20–40%.
METHODS
Study Design
We conducted a subgroup analysis from a recently published
cohort (10). In the current retrospective observational study, we
included patients with an acute ischemic stroke or TIA admitted
within 14 days of symptom onset, and a concomitant ipsilateral
symptomatic ICA-stenosis of 20–40% (measured according
to the NASCET criteria) without any other apparent stroke
etiology according to the Trial of Org 10,172 in Acute Stroke
Treatment (TOAST) (11), or a contralateral asymptomatic
ICA-stenosis of 20–40% in the Department of Neurology
(University Hospital of Würzburg) from January 2011 until
September 2016. The exclusion criteria were: (1) ischemic
stroke due to coronary angiography, carotid artery stenting, or
carotid endarterectomy (CEA), (2) absence of ultrasound scans,
or (3) bilateral stroke. In patients with bilateral ICA-stenosis
of 20–40%, we included the symptomatic side in the present
study and excluded the asymptomatic one to avoid including
the same patient in the two study groups. All patients received
the following minimal stroke work-up: routine blood tests
within 24 h after index-TIA or index-stroke, ECG-monitoring
with atrial fibrillation (AF) alarm for a minimum of 24-
h, transthoracic echocardiography, extra- and transcranial
color-coded duplex ultrasonography, and neuroimaging using
computed tomography (CT) and/or magnetic resonance
imaging (MRI).
Stroke was defined as acute-onset focal neurological deficits
with a corresponding brain lesion in a vascular distribution
showing hyperintensity in the diffusion-weighted images (DWI)
with a corresponding hypointensity in the apparent diffusion
coefficient (ADC) images and/or hypodensity in the cerebral
CT. If the patient did not undergo cerebral MRI, stroke was
diagnosed if the deficits persisted>24 h, with no other reasonable
etiology. TIA was diagnosed if the deficits did not lead to
brain lesions in the neuroimaging and the deficits persisted
<24 h. Hypertension was defined as the presence of any of
the followings: (1) persistent elevation of the systolic blood
pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg
requiring the initiation of antihypertensive drugs (12), or (2)
if the patient was previously diagnosed with hypertension and
has already received antihypertensive medications. Diabetes
mellitus was defined according to the following criteria: (1)
Hemoglobin A1c ≥ 6.5%, (2) Fasting blood glucose ≥126 mg/dl,
(3) Blood glucose ≥200 mg/d, 2 h after oral glucose tolerance
test (13), or (4) Previous diagnosis and treatment of diabetes
mellitus. The patients were diagnosed as active smokers if they
regularly consumed cigarettes within the previous 12 months.
Atrial fibrillation (AF) was diagnosed according to the following
criteria: (1) previously documented AF in the family physician’s
office prior to the index event or (2) 12-lead ECG or Holter
ECG recorded after the index event showing loss of p-waves
with irregular rapid heart rate and narrow QRS-complex for a
duration of at least 30 s.
Ultrasound Assessment of the Plaque
Length and Cross-Sectional Area
Ultrasound examination was conducted on a Toshiba AplioXG
machine (Toshiba Medical Systems Corporation, Tochigi, Japan)
using a 7.5 MHz linear array transducer. Ultrasound images
were assessed in our picture archiving and communication
system (PACS) by a single non-blinded examiner (AE). The
hemodynamic criteria of the NASCET were used to measure
the degree of stenosis (14). The stenotic length was measured
from the most proximal to the most distal stenotic end, in the
projection demonstrating the longest length, using a previously
publishedmethod (10). The stenotic ends were defined according
to the following criteria: (1) visible narrowing of the vascular
lumen, (2) flow turbulence in the proximal stenotic end. For
the distal end, this criterion was used to identify the distal
end only in the presence of Doppler waves showing increased
flow velocity. This is because there is no possible differentiation
between a flow turbulence resulting from increased systolic flow
velocity and that resulting from poststenotic flow disturbance,
and/or (3) calcification shadowing. For the assessment of the
plaque cross-sectional area, we used a previously published
method (8, 15). First, we identified the projection demonstrating
the largest cross-sectional area. Then we magnified the stored
images in our PACS. Thereafter, we outlined the plaque
edges using a cursor. Finally, the plaque cross-sectional
area was displayed on the screen. Figure 1 demonstrates
the measurement methods used for the plaque length and
cross-sectional area.
Statistical Analysis
Quantitative data were expressed using median and interquartile
range, while qualitative data were expressed in absolute values
and relative frequencies. To check for normality, we used a
histogram and the Shapiro-Wilk test. Univariable statistical tests
were conducted using χ2 test or Fischer exact test (if n <
5) for categorical data as well as Mann-Whitney U-test for
continuous data. We calculated the sensitivity and specificity of
plaque length and cross-sectional area using a receiver operating
characteristic (ROC)-curve. An AUC > 0.5 indicates better
prediction; values closer to 1 indicate more accurate prediction.
Univariate binary logistic regression analyses were performed
to measure the strength of association, measured as OR (95%
CI), between the occurrence of ischemic stroke or TIA in
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FIGURE 1 | Measurement method: Example for the method used to measure
the plaque length (dashed red line) and cross-sectional area (dashed yellow) in
a patient with symptomatic low-grade internal carotid artery stenosis of
20–40%.
relation to low-grade ICA-stenosis and other possibly related
variables. Variables with a p < 0.1 and our two study variables
(plaque cross-sectional area as well as plaque length) were further
assessed in a multivariate logistic regression model. The fitness
of this model was tested using a Hosmer-Lemeshow “goodness-
of-fit” test. Data were analyzed in SPSS software package
version 25 (SPSS, Chicago, IL, USA). P < 0.05 was considered
statistically significant.
RESULTS
Four hundred eighty-nine patients, who received the ICD10-
codes for stroke or TIA as well as ICA-stenosis, were screened
for our inclusion and exclusion criteria. Forty-one patients (27
asymptomatic and 14 symptomatic ICA-stenosis) were included
(See flow chart, Figure 2). The baseline characteristics are shown
in Table 1. The risk factors were similar between the two
groups. The plaque cross-sectional area was significantly larger
and the length was insignificantly longer for symptomatic than
asymptomatic ICA-stenosis; median (IQR) were 0.45 (0.21–0.69)
cm2 and 0.27 (0.21–0.38) cm2, p = 0.03, as well as 1.7 (1.5–
2.1), and 1.4 (1.1–1.8) cm, p = 0.15, respectively. Using a
ROC-curve (Figure 3), a plaque cross-sectional area ≥0.36 cm2
and a plaque length ≥1.65 cm were found to have a sensitivity
of 71 and 50% and a specificity of 76 and 64%, respectively,
for symptomatic compared to asymptomatic ICA-stenosis (for
cross-sectional area: AUC 0.72, 95% CI 0.53–0.91, p = 0.03,
whereas for length: AUC 0.64, 95% CI 0.46–0.82, p = 0.16).
In a sex-adjusted multivariate binary logistic regression model
(Table 2), a plaque cross-sectional area ≥0.36 cm2 and a plaque
length ≥1.65 cm were associated with an OR (95% CI) of
5.54 (1.2–25.6), p = 0.028, and 1.78 (0.36–8.73), p = 0.48,
respectively, for symptomatic compared to asymptomatic ICA-
stenosis. The Hosmer-Lemeshow “goodness-of-fit” test showed
a non-significant difference between the observed and expected
results with p= 0.076.
FIGURE 2 | Flow chart showing the inclusion and exclusion criteria for
patients enrolled in the present study. CA, carotid artery; CCA, common
carotid artery; ICA, internal carotid artery; TIA, transient ischemic attack,
iatrogenic stroke (5 cases after carotid endarterectomy, 1 case after coronary
angiography). Of the 489 patients screened, only 41 patients met our inclusion
and exclusion criteria.
DISCUSSION
Plaque Size May Represent a High-Risk
Plaque Feature
We found that the plaques of symptomatic low-grade ICA-
stenosis of 20–40% had a significantly larger cross-sectional area
and were insignificantly longer in comparison to asymptomatic
ICA-stenosis of 20–40%. Among our patients with ICA-stenosis
of 20–40%, a plaque cross-sectional area ≥0.36 cm2 had a
sensitivity of 71% and a specificity of 76% with an OR (95% CI)
of 5.54 (1.2–25.6) for symptomatic ICA-stenosis. We measured
the plaque area using a method similar to previous studies.
Taking the paucity of studies on plaque length into account, we
considered several elements (narrowing of the vascular lumen,
flow turbulence, increased flow velocity, and plaque calcification)
to increase the accuracy of our measurement method for the
plaque length. In line with our findings, the asymptomatic carotid
stenosis and risk of stroke study (ACSRS) showed that increased
plaque area, measured on ultrasound, is associated with increased
future ipsilateral stroke rate from asymptomatic ICA-stenosis of
12–99% (NASCET) (15). The median (IQR) plaque area in the
ACSRS study was 0.42 (0.27–0.6) cm2 and plaques>0.8 cm2 were
noticeably associated with higher ipsilateral stroke risk. Of note,
the ACSRC study included ICA-stenosis of 12–99%, whereas
our study was restricted to ICA-stenosis of 20–40%. Moreover,
previous studies reported that plaque thickness, length, and
volume were more prominent on the ipsilateral side among
patients with stroke (2, 4). Similarly, another study showed
that carotid plaque volume of the endarterectomy specimens
was larger in symptomatic than in asymptomatic ICA-stenosis
(mean, 0.97 vs. 0.74 cm3, p < 0.001) (16). Furthermore, the
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TABLE 1 | Baseline characteristics.
Characteristics Asymptomatic ICA-stenosis (n = 27) Symptomatic ICA-stenosis (n = 14) P-value
Age-year, median (IQR) 74 (67–81) 75 (59–83) 0.86
Male sex, no. (%) 13 (48.1) 11 (78.6) 0.1
Hypertension, no. (%) 26 (96.3) 12 (85.7) 0.27
Diabetes mellitus, no. (%) 10 (37) 4 (28.6) 0.73
Active smoking, no. (%) 6 (22.2) 3 (21.4) 1
AF, no. (%) 11 (40.7) Exclusion criteria
Previous treatment
Antiplatelets, no. (%) 14 (51.9) 9 (64.3)
Anticoagulants, no. (%) 6 (22.2) 2 (14.3)
Statins, no. (%) 5 (18.5) 7 (50)
Antihypertensive drugs, no. (%) 19 (70.4) 11 (78.6)
Ischemic cerebrovascular event 0.72
Stroke, no. (%) 20 (74.1) 9 (64.3)
TIA, no. (%) 7 (25.9) 5 (35.7)
Time from stroke onset to admission-days, median (IQR) 1 (1–1) 1 (1–2)
NIHSS-score on admission, median (IQR) 2 (0–7) 1 (0–3) 0.22
HbA1c (%), median (IQR) 6.1 (5.7–7.2) 6.2 (5.4–6.5) 0.45
LDL-cholesterol (mg/dl), median (IQR) 115 (87.5–164) 105 (94–133) 0.57
Hemoglobin (mg/dl), median (IQR) 13.6 (12–14.7) 14.1 (13.7–14.8) 0.16
Plaque size in cm2, median (IQR) 0.27 (0.21–0.38) 0.45 (0.21–0.69) 0.03*
Plaque size ≥ 0.36 cm2, no. (%) 7 (25.9) 10 (71.4) 0.008*
Plaque length in cm, median (IQR) 1.4 (1.1–1.8) 1.7 (1.5–2.1) 0.15
Acute treatment with IV alteplase, no. (%) 4 (14.8) 2 (14.3) 1
*Statistically significant results.
AF, atrial fibrillation; HbA1c, hemoglobin A1c; ICA, internal carotid artery; IQR, interquartile range; LDL-cholesterol, low density lipoprotein cholesterol; mRS, modified Rankin scale;
NIHSS, national institute of health stroke scale; TIA, transient ischemic attack.
total areas of all plaques in the right carotid artery, measured
on ultrasound, were a strong predictor of ischemic stroke
(9). Another study showed that the total carotid plaque areas
on ultrasound in both carotid arteries were positively related
to the combined 5-year risk of stroke, myocardial infarction,
and vascular death (8). In a population-based study, larger
plaque thickness (17), or carotid intima-media thickness (18, 19)
were found to bear a higher risk for future major vascular
events. Conversely, Nandalur et al. reported no difference
between carotid plaque volume, measured by multidetector CT,
among symptomatic compared to asymptomatic ICA-stenosis
(20). Of note, a prominent inverse correlation between the
degree and length of stenosis was reported among patients
with symptomatic ICA-stenosis ≥ 70% but neither among
symptomatic ICA-stenosis<70% nor among asymptomatic ICA-
stenosis (10). Interestingly, statin was found to slow plaque
progression, and even led to regression of the carotid plaques.
This effect was mainly shown with maintaining the serum
level of low-density lipoprotein <100 mg/dl independent of
the statin dose (21). Plaque size can be used to stratify the
cardio- or cerebrovascular risk and to monitor response to
treatment (8, 15).
Other High-Risk Plaque Features
Several researchers investigated high-risk plaque features.
Demarco et al. found that the following plaque features, assessed
on magnetic resonance angiography (MRA), were more frequent
among symptomatic mild-to-moderate ICA-stenosis compared
to asymptomatic mild-to-moderate stenosis: thin or ruptured
fibrous cap (100 vs. 36%, p = 0.006), lipid-rich necrotic core
(100 vs. 39%, p = 0.022), and -to a lesser extent- plaque
hemorrhage (86 vs. 33%, p = 0.055) (5). A meta-analysis showed
that intraplaque hemorrhage (IPH), defined as the presence
of a hyperintense signal within the carotid plaque on T1-
weighted fat-suppressed MRI images, is associated with an
annual stroke/TIA rate of 17.71% compared to 2.43% in relation
to plaques without hemorrhage (22). The authors noted that
IPH was associated with a hazard ratio [HR] of 5.69 (95% CI
2.98–10.87) for stroke/TIA. However, optimal medical treatment
was not accurately implemented for patients included in the
aforementioned meta-analysis; only 62% of the patients had
a statin and 72% had an antiplatelet therapy, whereas data
regarding further elements of optimal medical treatment are
not available. Another meta-analysis identified the following
high-risk ultrasound plaque features: plaque neovascularity (OR
19.68, 95% CI 3.14–123.16), complex plaque (OR 5.12, 95%
CI 3.42–7.67), plaque ulceration (OR 3.58, 95% CI 1.66–7.71),
plaque echolucency (OR 3.99, 95%CI 3.06–5.19), and intraplaque
motion (OR = 1.57, 95% CI = 1.02–2.41) (23). Of note,
hypoechoic plaque morphology is more often associated with
intraplaque hemorrhage (24), and is notably related to fatal
or disabling stroke (15). Plaque inflammation on PET/CT was
also identified as a high-risk feature (25). Interestingly, the
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ACSRS study showed that the combination of high-risk clinical
features, high-risk plaque features, and the degree of stenosis
could better stratify the risk of ipsilateral stroke/TIA (15). The
authors of the aforementioned study identified the following
high-risk plaque features: hypoechoic plaque morphology or
low gray scale median (GSM), increased plaque area, and the
presence of discrete white areas without acoustic shadowing.
For example, the authors showed a 5-year ipsilateral stroke
FIGURE 3 | Receiver operating characteristics curve (ROC) showing the
relation between plaque surface area (blue) and length (green) with ipsilateral
ischemic manifestations. A cut-off plaque cross-sectional area of ≥0.36 cm2
(indicated by the red circle) yielded a sensitivity of 71% and a specificity of
76% for the development of ipsilateral manifestations; AUC (95% CI) = 0.72
(0.53–0.91), p = 0.03. A cut-off plaque length of ≥1.65 cm (indicated by the
red circle) yielded a sensitivity of 50% and a specificity of 64% for the
development of ipsilateral manifestations; AUC (95% CI) = 0.64 (0.46–0.82),
p = 0.16.
rate of 70.4% among patients with the following combinations:
asymptomatic ICA-stenosis of 50–82% (NASCET), history of
contralateral stroke/TIA, discrete white areas, plaque area >0.8
cm2, and low GSM <15. Conversely, the 5-year ipsilateral
stroke rate was as low as 1.9% for patients with the following
combinations: asymptomatic ICA-stenosis 83–99% (NASCET),
no history of contralateral stroke/TIA, absence of discrete white
areas, plaque area <0.4 cm2, and GSM >30. Of note, the ACSRS
study was conducted before the era of optimal medical treatment,
so that the aforementioned 5-year ipsilateral stroke rates of 70.4%
and 1.9% should be viewed with caution. This elucidates the
importance of risk stratification using multiple high-risk clinical
and plaque features rather than a single one. The follow-up of
these features might be used to optimize medical treatment or to
investigate new medical therapies for cerebrovascular and other
major vascular events.
High-Risk Plaque Features Represent a
Fruitful Subject for Future Research
More than 20 years ago, CEA was shown to provide an
overall stroke prevention benefit in symptomatic patients with
ICA-stenosis ≥50% (26–29). However, these data should be
interpreted with caution, because they were conducted before
the introduction of optimized medical treatment. The latter
includes antiplatelets, statins, control of blood pressure and blood
glucose level, smoking cessation, implementation of exercise
programs, Mediterranean diet, and lifestyle modification, and
was shown to significantly reduce the stroke risk among patients
with asymptomatic ICA-stenosis (30, 31). Current optimized
medical treatment is an established therapy for prevention of
arterial disease complications, including patients with carotid
stenosis, whether mild or severe, and it is a continually improving
gold standard of care (32, 33), and should also be offered
perioperatively before CEA (34). Best medical treatment seems to
be as effective as CEA or carotid artery stenting for asymptomatic
TABLE 2 | Factors related to the occurrence of stroke or transient ischemic attack ipsilateral to a low-grade stenosis in the binary logistic regression models.
Characteristic Univariate regression analysis Multivariate regression analysis
OR 95% CI P OR 95% CI P
Age 0.98 0.93–1.05 0.6
Male sex 3.91 0.9–17.4 0.07 3.7 0.7–19.45 0.12
Hypertension 0.23 0.02–2.8 0.25
Diabetes mellitus 0.68 0.17–2.75 0.59
Active smoking 0.96 0.2–4.57 0.95
HbA1c (%) 0.77 0.39–1.54 0.46
LDL-cholesterol (mg/dl) 0.99 0.98–1.01 0.35
Hemoglobin (mg/dl) 1.56 0.91–2.67 0.1
Plaque length ≥1.65 cm 2 0.54–7.47 0.3 1.78 0.36–8.73 0.48
Plaque cross–sectional area ≥0.36 cm2 7.14 1.69–30.27 0.008* 5.54 1.2–25.6 0.028*
H-L-Testa 0.076
*Statistically significant results.
CI, confidence interval; HbA1c, hemoglobin A1c; LDL-cholesterol, low-density lipoprotein cholesterol; OR, odds ratio.
aHosmer-Lemeshow “goodness-of-fit test for the multivariate regression analysis showed a non-significant p-value (p = 0.076) for the difference between our observed results and the
expected results. The non-significant p-value for this test means better fit of the model (the higher the value, the better the fit).
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moderate-to-severe ICA-stenosis (30, 31, 33). Additionally,
medical treatment is around 3–8 times more cost-effective than
carotid procedures (33). Of note, under suboptimal medical
treatment, the annual ipsilateral stroke rate associated with mild-
to-moderate asymptomatic ICA-stenosis is 0.1–1.6% and 2–3.3%
in severe asymptomatic ICA-stenosis (6, 7). Under best medical
treatment, an average annual stroke rate among moderate-to-
severe asymptomatic ICA-stenosis ranges from 0.3–3.1% (31). In
the current work, large-sized plaques were shown to represent
a high-risk plaque feature. The incidence of ipsilateral stroke
associated with high-risk plaque features, and the protective
effect of best medical treatment, as well as carotid procedures
for those high-risk plaques, remain under-investigated. We
recommend the assessment of this risk in future observational
studies. If any subgroup can be identified with high-risk for
ipsilateral stroke, despite best medical treatment, it is important
to further test the cost-benefit ratio of carotid procedures for
those patients in randomized trials before the results can be
translated into the clinical practice.
Study Limitations
We are aware of the following limitations: First, the sample
size is small. However, this study was planned as a pilot study
and serves as a proof-of-concept. Second, the design of the
present study is retrospective and has to be confirmed in large
prospective observational studies to stratify the risk related to
different degrees of ICA-stenosis and high-risk plaque features.
This allows assessing whether there is a subgroup with an
ipsilateral stroke rate high enough to justify the conduction of
trials of more intensive/different medical intervention and/or
carotid procedures. Third, the assessment of the plaque length
and surface area was performed by a non-blinded investigator,
which represents another study limitation. Fourth, there is a
bias of a sub-group analysis from a non-predefined primary
outcome. Fifth, other individual risk factors, other plaque
characteristics, and previous medications may have influenced
our comparative analysis.
CONCLUSION
Large plaques might represent a high-risk marker for further
complication of arterial disease including ipsilateral stroke
among patients with low-grade ICA-stenosis. Sufficiently
powered prospective longitudinal cohort studies are needed
to definitively test the stroke risk stratification value of
carotid plaque length and cross-sectional area in the setting
of current optimal medical treatment. Plaque size, along
with other high-risk plaque features and high-risk clinical
features should be ideally used to optimize the medical
treatment of patients with carotid stenosis as well as other
atherosclerotic vascular diseases. Future observational
studies are needed to stratify the risk of ipsilateral stroke
associated with high-risk clinical features, along with high-
risk plaque features among different stenotic degrees. This
probably allows to identify subgroups of patients with
a risk high enough to justify the conduction of future
randomized trials.
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